DefEYE

Executive Summary

DefEYE, Inc. is a Boston-based privately held ophthalmic medical device company founded in 2020, dedicated to developing and commercializing decellularized biologic solutions for ocular surface disease and ocular surgery. Its lead product, BIOVANCE® 3L Ocular, is a first-in-class decellularized basement membrane with a unique triple-layer design that mimics the native ocular surface environment. This innovative scaffold aims to promote corneal healing and reduce scarring in indications such as limbal stem cell deficiency, chemical burns, and pterygium surgery. The company addresses a significant unmet need in ophthalmology, where current options like amniotic membrane grafts face limitations in consistency, availability, and handling. DefEYE's decellularized approach offers a potentially superior alternative with enhanced transparency, strength, and bioactivity.

Upcoming Catalysts (preview)

• Q3 2026Initiation of pivotal clinical trial for BIOVANCE® 3L Ocular70% success
• Q2 2027FDA 510(k) clearance or breakthrough device designation55% success
• Q4 2026Strategic partnership or licensing deal for distribution50% success